Close

UPDATE: BTIG Downgrades Neuronetics (STIM) to Neutral on Q3 Revenue Shortfall

Go back to UPDATE: BTIG Downgrades Neuronetics (STIM) to Neutral on Q3 Revenue Shortfall

Neuronetics (STIM) PT Lowered to $15 at Canaccord Genuity

October 13, 2021 8:06 AM EDT

Canaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $15.00 (from $21.00) while maintaining a Buy rating on weaker Q3 revenue.

The analyst commented, "Neuronetics announced preliminary Q3/21 revenue of ~$13.8M, missing our $15.0M estimate, and the companys guidance of $15M-$16M. Management commentary from the preannouncement indicated... More

Neuronetics Inc. (STIM) Prelim. Q3 Revenue Falls Short of Prior Guidance

October 12, 2021 4:18 PM EDT

Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today provided preliminary revenue results for the third quarter of 2021.

The Company expects total revenue for the third quarter to be approximately $13.8... More